Neuropeptide Y family of hormones: receptor subtypes and antagonists
- PMID: 9145434
- DOI: 10.1016/s0196-9781(96)00347-6
Neuropeptide Y family of hormones: receptor subtypes and antagonists
Abstract
Neuropeptide Y (NPY) is the most abundant peptide present in the mammalian central and peripheral nervous system. NPY exhibits a variety of potent central and peripheral effects including those on feeding, memory, blood pressure, cardiac contractility and intestinal secretions. Classical pharmacological studies have shown that NPY effects are mediated by four different receptor subtypes, Y-1, Y-1-like, Y-2, and Y-3. However, the existence of numerous atypical activities provide strong evidence for the occurrence of additional NPY receptor subtypes. Pharmacological studies have further been facilitated by the recent cloning and expression of Y-1, Y-2, Y-4 (PP-1) and Y-5 receptors. Moreover, the cloned Y-5 receptor has been suggested to be the long awaited Y-1-like receptor involved in feeding. Structure-activity studies have laid a good foundation towards the development of receptor selective compounds, and to date potent Y-1 selective peptide and nonpeptide antagonists have been developed. The need to clone numerous receptor subtypes and to develop receptor selective compounds for physiological and perhaps clinical use is expected to keep NPY research active for many years to come.
Similar articles
-
The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.Biochem Biophys Res Commun. 1999 Dec 9;266(1):88-91. doi: 10.1006/bbrc.1999.1750. Biochem Biophys Res Commun. 1999. PMID: 10581170
-
Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?J Pharmacol Exp Ther. 1999 May;289(2):1031-40. J Pharmacol Exp Ther. 1999. PMID: 10215684
-
Is there really an NPY Y3 receptor?Regul Pept. 1998 Sep 25;75-76:71-8. doi: 10.1016/s0167-0115(98)00054-8. Regul Pept. 1998. PMID: 9802395
-
Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.J Pept Sci. 2000 Mar;6(3):97-122. doi: 10.1002/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E. J Pept Sci. 2000. PMID: 10759209 Review.
-
Novel modified and radiolabelled neuropeptide Y analogues to study Y-receptor subtypes.Neuropeptides. 2004 Aug;38(4):153-61. doi: 10.1016/j.npep.2004.04.002. Neuropeptides. 2004. PMID: 15337368 Review.
Cited by
-
Neuropeptide Y/Y5 Receptor Pathway Stimulates Neuroblastoma Cell Motility Through RhoA Activation.Front Cell Dev Biol. 2021 Feb 17;8:627090. doi: 10.3389/fcell.2020.627090. eCollection 2020. Front Cell Dev Biol. 2021. PMID: 33681186 Free PMC article.
-
The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability.J Mol Cell Cardiol. 2012 Mar;52(3):667-76. doi: 10.1016/j.yjmcc.2011.11.016. Epub 2011 Dec 7. J Mol Cell Cardiol. 2012. PMID: 22172449 Free PMC article.
-
Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis.Respir Res. 2018 Aug 6;19(1):149. doi: 10.1186/s12931-018-0846-4. Respir Res. 2018. PMID: 30081920 Free PMC article. Review.
-
Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density.Neuropeptides. 2018 Feb;67:45-55. doi: 10.1016/j.npep.2017.11.005. Epub 2017 Nov 7. Neuropeptides. 2018. PMID: 29129406 Free PMC article.
-
Neuropeptide Y mediates cardiac hypertrophy through microRNA-216b/FoxO4 signaling pathway.Int J Med Sci. 2021 Jan 1;18(1):18-28. doi: 10.7150/ijms.51133. eCollection 2021. Int J Med Sci. 2021. PMID: 33390770 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous